{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-091733","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2025-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.838859+00:00","generated_at":"2026-05-17T06:07:34.107206+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Acurx shareholders approve warrant exercise and authorized share increase at special meeting","bullets":["Proposal 1 (warrant exercise for Nasdaq compliance): 8,816,581 for, 602,155 against, 9,823,429 broker non-votes.","Proposal 2 (authorized share increase 200M to 250M): 16,476,460 for, 2,526,119 against, 363,000 abstentions.","Proposal 3 (adjournment) approved: 16,538,163 for, 2,271,234 against, 556,182 abstentions.","Quorum: 19,365,579 shares (63.44%) of 30,524,540 outstanding shares represented."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-091733","json":"https://secwatch.observer/filing/0001104659-25-091733.json","markdown":"https://secwatch.observer/filing/0001104659-25-091733.md","text":"https://secwatch.observer/filing/0001104659-25-091733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925091733/0001104659-25-091733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925091733/tm2526531d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:07:34.107206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}